Comparative Pharmacology
Head-to-head clinical analysis: BUTABARBITAL versus SODIUM BUTABARBITAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTABARBITAL versus SODIUM BUTABARBITAL.
BUTABARBITAL vs SODIUM BUTABARBITAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Butabarbital is a barbiturate that acts as a central nervous system depressant. It enhances the activity of GABA, an inhibitory neurotransmitter, by binding to the GABA-A receptor and prolonging the opening of chloride ion channels, leading to neuronal hyperpolarization and reduced excitability.
Barbiturate that enhances GABA-A receptor activity, increasing chloride ion conductance and causing CNS depression.
50-100 mg orally or intramuscularly 3-4 times daily; maximum 400 mg/day.
50-100 mg orally or intramuscularly 3-4 times daily as a sedative; 100-200 mg orally or intramuscularly for preoperative sedation.
None Documented
None Documented
Terminal elimination half-life is 30-50 hours in adults, which may be prolonged in elderly or patients with hepatic impairment, leading to accumulation with repeated dosing.
Clinical Note
moderateButabarbital + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Butabarbital is combined with Fluticasone propionate."
Clinical Note
moderateButabarbital + Haloperidol
"The risk or severity of adverse effects can be increased when Butabarbital is combined with Haloperidol."
Clinical Note
moderateButabarbital + Clemastine
"The risk or severity of adverse effects can be increased when Butabarbital is combined with Clemastine."
Clinical Note
moderateTerminal elimination half-life 40-60 hours in adults; prolonged in hepatic impairment and elderly.
Primarily renal, with approximately 60-80% of the dose eliminated as metabolites (mostly hydroxylated and conjugated) and less than 5% as unchanged drug. Minor biliary/fecal excretion occurs (<10%).
Renal excretion of unchanged drug and metabolites; approximately 30-50% as unchanged drug in urine. Minor fecal elimination (<5%).
Category C
Category C
Barbiturate
Barbiturate
Butabarbital + Venlafaxine
"The risk or severity of adverse effects can be increased when Butabarbital is combined with Venlafaxine."